Tandem Diabetes Care has received FDA clearance for its Control-IQ+ automated insulin delivery (AID) technology, expanding its use to adults with type 2 diabetes. Previously approved for type 1 diabetes, Control-IQ+ integrates with the t:slim X2 and Tandem Mobi insulin pumps, adjusting insulin delivery based on real-time glucose readings from a continuous glucose monitor (CGM).

The expanded indication follows a pivotal trial involving over 300 individuals with type 2 diabetes, comparing the system's performance to traditional multiple daily injections. Study results will be presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam next month.

Tandem's latest clearance marks a significant step in automated diabetes management, addressing a population of over 2 million Americans requiring intensive insulin therapy. The company anticipates making Control-IQ+ available to new and existing users in the U.S. starting in March 2025.

For more information, please visit Fierce Biotech.